Skip to Content

Posts tagged with "Alzheimer’s Disease"

  • Alzheimer's Disease

    A New Way to Make GSK3 Inhibitors

    Of the discovery of GSK3 (glycogen synthase kinase 3) inhibitors there has been no end. I first came across it as a target it about 1997, and even then, once I started reading the literature, I quickly felt as if I were late to the party. It’s been investigated for diabetes (and other metabolic diseases), Alzheimer’s… Read More
  • Alzheimer's Disease

    The Best Beta-Secretase Inhibitor Yet in Alzheimer’s

    Merck has published new results on their latest Alzheimer’s drug candidate, the beta-secretase inhibitor verubecestat (MK-8931). The paper in Science Translational Medicine is quite interesting, both for what it says and what it doesn’t (or can’t, yet). BACE inhibitors have had quite a time of it over the years. Coming up with a m… Read More
  • Alzheimer's Disease

    The Limits of Big Data

    I fear that mentioning the phrase “Big Data” in the first sentence of a blog post will make half the potential readers suddenly remember that they have podiatrist appointments or something. But that’s the only way to approach this article at Wired. After all, the title is “The Cure For Cancer is Data – Mountains of… Read More
  • Alzheimer's Disease

    Bill Gates and His Moonshot

    The rocket’s supposed to be moving, and it probably is, but everyone knows that you can’t see that with the naked eye. Not at first. The announcer said “Lift-off” – well, that probably happened sometime during the lunch hour, it’s easy to miss – and the first thing you look for is the exhaust starting… Read More
  • Alzheimer's Disease

    Just How Worthless Are the Standard Alzheimer’s Models?

    As mentioned yesterday, Alzheimer’s therapies have, for the most part, been a cliff over which people push bales of money. There are plenty of good reasons for this: we don’t really know what the cause of Alzheimer’s is, when you get down to it, and we’re the only animal that we know of that gets… Read More
  • Alzheimer's Disease

    Does Axovant Have Any Hope in Alzheimer’s?

    Hey, remember Axovant? That’s the company that acquired a shelved Alzheimer’s candidate from GSK (intepirdine) and promptly went public in June of 2015 at what seemed a ridiculous valuation ($15/share, raising $315 million). People certainly made money on it, but jeez, the whole business really had a nasty look to it. The company’… Read More
  • Alzheimer's Disease

    TauRx Reports on Their Alzheimer’s Drug. Unfortunately.

    It’s been a while since we heard from TauRx, the company that’s been developing an unusual Alzheimer’s therapy targeting tau protein instead of amyloid. They released interesting Phase II data some time ago, but they’ve been improving their formulation and going into a larger, longer Phase III, which is what anyone working… Read More
  • Alzheimer's Disease

    Muscarinic Agonists Come Back Around

    Allergan, now that they’re not going to be Pfizer, has wasted no time signing a big deal with Heptares for Alzheimer’s. Heptares, as the receptor-centric people in the readership will know well, has been working on GPCR structure for some years now, and applying this knowledge to their own drug discovery efforts. They have what… Read More
  • Alzheimer's Disease

    Is Lilly’s Big Alzheimer’s Trial in Trouble?

    Eli Lilly has been testing their solanezumab antibody against Alzheimer’s for some years now. The first rounds of clinical trials were. . .inconclusive at best. Perhaps there was a bit of an effect in the mildest-affected patient cohort, perhaps not. The company went for it, though, starting a second Phase III in a more carefully selected p… Read More
  • Alzheimer's Disease

    Microbial Alzheimer’s: The Arguing Continues

    The Journal of Alzheimer’s Disease has published an editorial, signed by thirty-one researchers from institutions across several continents, calling on a re-evaluation of the disease’s origins: We are researchers and clinicians working on Alzheimer’s disease (AD) or related topics, and we write to express our concern that one particu… Read More
...234...